Astrazeneca (AZN) Total Non-Current Liabilities (2009 - 2026)

Astrazeneca has reported Total Non-Current Liabilities for 18 years, with the latest figure at -$967.0 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 0.51% year-over-year to -$967.0 million in Q2 2026; TTM through Jun 2026 was -$967.0 million, a 0.51% increase from a year earlier, with the FY2025 full-year figure at -$918.0 million, changed 0.33% from the prior year.
• Total Non-Current Liabilities was -$967.0 million for Q2 2026 at Astrazeneca, up from -$34.1 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was -$892.0 million in Q2 2022, with the low at -$41.2 billion in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is -$18.3 billion, with a median of -$15.8 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities rose 21.71% in 2022, then sank 52.13% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at -$896.0 million in 2022, then slipped by 25.78% to -$1.1 billion in 2023, then grew by 18.28% to -$921.0 million in 2024, then grew by 0.33% to -$918.0 million in 2025, then fell by 5.34% to -$967.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at -$967.0 million (Q2 2026), -$34.1 billion (Q1 2026), and -$918.0 million (Q4 2025), per Business Quant data.